Journal: CNS Drugs

Article Title: Polypharmacy Among Headache Patients: A Cross-Sectional Study

doi: 10.1007/s40263-018-0522-8

Figure Lengend Snippet: Therapeutic classes of medications taken by the 291 patients for acute treatment and comparison between chronic and episodic headache patients (some patients took more than one symptomatic drug)

Article Snippet: Patients with chronic headache took triptans ( P < 0.0001), analgesic combinations (P < 0.05) and opioids ( P < 0.005) (Chi square tests) significantly more than patients with episodic headache.

Techniques: Medications, Comparison

Journal: CNS Drugs

Article Title: Polypharmacy Among Headache Patients: A Cross-Sectional Study

doi: 10.1007/s40263-018-0522-8

Figure Lengend Snippet: Multivariate logistic regression analysis for risk factors of polypharmacy among the 300 primary headache patients

Article Snippet: Patients with chronic headache took triptans ( P < 0.0001), analgesic combinations (P < 0.05) and opioids ( P < 0.005) (Chi square tests) significantly more than patients with episodic headache.

Techniques:

Journal: Pain and Therapy

Article Title: The Role of the Combination Paracetamol/Caffeine in Treatment of Acute Migraine Pain: A Narrative Review

doi: 10.1007/s40122-024-00581-x

Figure Lengend Snippet: Recommendations for acute treatment of headache from guidelines

Article Snippet: Triptans + NSAIDs or other drugs , Migraine , Multitarget combination therapy with a triptan plus an NSAID is more effective in acute migraine treatment than monotherapy with either drug alone; equal to superior pain relief (2-h pain response) , 11 studies, multiple triptans evaluated in different combinations with NSAIDs: sumatriptan, rizatriptan, almotriptan; multiple NSAIDs evaluated: tolfenamic acid, naproxen sodium, rofecoxib, trimebutine, paracetamol, aceclofenac Primary endpoint: recurrence rate of migraine attacks 1,2,6,7 ; 24-h pain relief response 3 ; 2-h pain relief 4,8,9,11 ; pain-free response at 2 h and 24-h sustained pain-free response (co-primary endpoints) 5,10 , 1. Krymchantowski AV, et al. Cephalalgia 1999, 19 2. Krymchantowski AV. Arq Neuropsiquiatr 2000, 58:428–430 3. Smith TR et al. Headache 2005, 45:983–991 4. Brandes JL, et al. JAMA 2007 297:1443–1454 5. Lipton RB et al. Cephalalgia 2009, 29:826–836 6. Krymchantowski AV. Cephalalgia 2002, 22:309–312 7. Krymchantowski AV. BMC Neurol 2004, 4:10 8. Krymchantowski AV et al. Cephalalgia 2006, 26:871–874 9. Freitag F et al. Headache 2008, 48 10. Schoenen J et al., the Belgian Headache Society. Cephalalgia 2008, 28:1095–1105 11. Brandes et al. JAMA 2007,297:1443–1454.

Techniques: Biomarker Discovery, Medications

Journal: Pain and Therapy

Article Title: The Role of the Combination Paracetamol/Caffeine in Treatment of Acute Migraine Pain: A Narrative Review

doi: 10.1007/s40122-024-00581-x

Figure Lengend Snippet: Combination therapy

Article Snippet: Triptans + NSAIDs or other drugs , Migraine , Multitarget combination therapy with a triptan plus an NSAID is more effective in acute migraine treatment than monotherapy with either drug alone; equal to superior pain relief (2-h pain response) , 11 studies, multiple triptans evaluated in different combinations with NSAIDs: sumatriptan, rizatriptan, almotriptan; multiple NSAIDs evaluated: tolfenamic acid, naproxen sodium, rofecoxib, trimebutine, paracetamol, aceclofenac Primary endpoint: recurrence rate of migraine attacks 1,2,6,7 ; 24-h pain relief response 3 ; 2-h pain relief 4,8,9,11 ; pain-free response at 2 h and 24-h sustained pain-free response (co-primary endpoints) 5,10 , 1. Krymchantowski AV, et al. Cephalalgia 1999, 19 2. Krymchantowski AV. Arq Neuropsiquiatr 2000, 58:428–430 3. Smith TR et al. Headache 2005, 45:983–991 4. Brandes JL, et al. JAMA 2007 297:1443–1454 5. Lipton RB et al. Cephalalgia 2009, 29:826–836 6. Krymchantowski AV. Cephalalgia 2002, 22:309–312 7. Krymchantowski AV. BMC Neurol 2004, 4:10 8. Krymchantowski AV et al. Cephalalgia 2006, 26:871–874 9. Freitag F et al. Headache 2008, 48 10. Schoenen J et al., the Belgian Headache Society. Cephalalgia 2008, 28:1095–1105 11. Brandes et al. JAMA 2007,297:1443–1454.

Techniques: Control

Journal: Neurological Sciences

Article Title: Acute treatment of migraine: quantifying the unmet need through real-world data in Italy

doi: 10.1007/s10072-024-07493-w

Figure Lengend Snippet: Flow diagram of patients interrupting triptans and no triptans patients

Article Snippet: Subjects with migraine who interrupted treatment with triptans (i.e., triptan withdraw cohort) were 605 on IQVIA LPD: This number translated into an estimate of around 29,300 individuals who interrupt treatment with triptans over a 1-year period and at national level; within the cohort of no triptan prescriptions, subjects with a recorded CV condition were 621 based on IQVIA LPD data: This number translated into an estimate of around 30,100 patients who have CV contraindications over a 1-year period and at national level.

Techniques:

Journal: Neurological Sciences

Article Title: Acute treatment of migraine: quantifying the unmet need through real-world data in Italy

doi: 10.1007/s10072-024-07493-w

Figure Lengend Snippet: Demographic and baseline clinical characteristics of patients interrupting triptans and no triptans patients

Article Snippet: Subjects with migraine who interrupted treatment with triptans (i.e., triptan withdraw cohort) were 605 on IQVIA LPD: This number translated into an estimate of around 29,300 individuals who interrupt treatment with triptans over a 1-year period and at national level; within the cohort of no triptan prescriptions, subjects with a recorded CV condition were 621 based on IQVIA LPD data: This number translated into an estimate of around 30,100 patients who have CV contraindications over a 1-year period and at national level.

Techniques:

Journal: Neurological Sciences

Article Title: Acute treatment of migraine: quantifying the unmet need through real-world data in Italy

doi: 10.1007/s10072-024-07493-w

Figure Lengend Snippet: Top 10 of most frequently prescribed molecules during baseline period for patients interrupting triptans and no triptans patients

Article Snippet: Subjects with migraine who interrupted treatment with triptans (i.e., triptan withdraw cohort) were 605 on IQVIA LPD: This number translated into an estimate of around 29,300 individuals who interrupt treatment with triptans over a 1-year period and at national level; within the cohort of no triptan prescriptions, subjects with a recorded CV condition were 621 based on IQVIA LPD data: This number translated into an estimate of around 30,100 patients who have CV contraindications over a 1-year period and at national level.

Techniques:

Journal: Neurological Sciences

Article Title: Acute treatment of migraine: quantifying the unmet need through real-world data in Italy

doi: 10.1007/s10072-024-07493-w

Figure Lengend Snippet: Presence of cardiovascular conditions representing triptans contraindications among no triptans patients

Article Snippet: Subjects with migraine who interrupted treatment with triptans (i.e., triptan withdraw cohort) were 605 on IQVIA LPD: This number translated into an estimate of around 29,300 individuals who interrupt treatment with triptans over a 1-year period and at national level; within the cohort of no triptan prescriptions, subjects with a recorded CV condition were 621 based on IQVIA LPD data: This number translated into an estimate of around 30,100 patients who have CV contraindications over a 1-year period and at national level.

Techniques: